"During the first quarter of the year, we commenced the nationwide launch of AmnioFix® Injectable, our newest tissue offering," commented Bill Taylor, President and COO. "AmnioFix® Injectable is an allograft composed of micronized amniotic tissue that is injectable and offers surgeons a clear advantage due to its natural ability to reduce inflammation at the injection site and enhance soft tissue healing of micro-tears in tendon tissue. The initial reception for AmnioFix® Injectable has been very gratifying, and it should be a significant contributor to our continued growth. We are excited about the potential of our AmnioFix® technology and very pleased that the physicians doing procedures for the soft tissue trauma, nerve and tendon protection, spinal applications and sports medicine markets are embracing our offerings."
The Company also reported that it has received a positive preliminary decision for the Q-Code from the Centers for Medicare and Medicaid Services (CMS) for its EpiFix® allograft. If confirmed in November 2012, it will be effective January 1, 2013. In the fourth quarter of 2011, MiMedx was awarded the Epifix® C-Code. The Q-Code is the next step for MiMedx in the reimbursement process through CMS and another significant indicator in the acceptance by CMS of the uses of the Company's wound care allograft in treating Medicare patients with chronic wounds. The Q-Code will replace the C-Code and will be the foundation for EpiFix® reimbursement long term.
Balance Sheet and Other FinancialsThe Company
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved